Antiphospholipid antibodies and lipoprotein(a) in obese children

Devis Pascut, Tanja Princi, Michela Donato, Giorgio Tamaro, Sergio Parco

Research output: Contribution to journalArticle

Abstract

Aim: Antiphospholipid (aPL) antibodies, Lipoprotein(a) [Lp(a)] and obesity are considered three independent risk factors for development of cardiovascular diseases. We investigate the presence of aPL antibodies and the Lp(a) concentration in 190 obese and 30 healthy children divided into prepubertal and pubertal, compared with healthy adults. Results: aPL antibodies were detected in 2.65% of prepubertal and in 2.59% of pubertal obese children. Considering results obtained by Lp(a) test, 4.4% of prepubertal and 5.2% of pubertal obese children and 17.5% of healthy adults were at risk for development of cardiovascular diseases. Conclusion: The presence of various prothrombotic risk factors increases the probability of developing thrombosis. Considering aPL antibodies there is no statistically significant difference among the different considered groups; therefore each category has the same risk factor. The Lp(a) distribution in adults is significantly different from the Lp(a) distribution in prepubertal (p = 0.012) and pubertal (p = 0.029) obese children. There is no significant difference among prepubertal subjects (p = 0.632) as well as pubertal subjects (p = 0.465), independently from the BMI. These results suggest the control of BMI in young population to avoid the presence of the obesity as another independent prothrombotic risk factor to be added to aPL and Lp(a) in the future adulthood.

Original languageEnglish
Pages (from-to)703-707
Number of pages5
JournalActa Paediatrica, International Journal of Paediatrics
Volume98
Issue number4
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Antiphospholipid Antibodies
Lipoprotein(a)
Antibodies
Cardiovascular Diseases
Obesity
Thrombosis
Population

Keywords

  • Antiphospholipid antibodies
  • Children
  • Lipoprotein(a)
  • Obesity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Antiphospholipid antibodies and lipoprotein(a) in obese children. / Pascut, Devis; Princi, Tanja; Donato, Michela; Tamaro, Giorgio; Parco, Sergio.

In: Acta Paediatrica, International Journal of Paediatrics, Vol. 98, No. 4, 04.2009, p. 703-707.

Research output: Contribution to journalArticle

Pascut, Devis ; Princi, Tanja ; Donato, Michela ; Tamaro, Giorgio ; Parco, Sergio. / Antiphospholipid antibodies and lipoprotein(a) in obese children. In: Acta Paediatrica, International Journal of Paediatrics. 2009 ; Vol. 98, No. 4. pp. 703-707.
@article{1dbedc6d19dc49c1a1510f1d2d6305a8,
title = "Antiphospholipid antibodies and lipoprotein(a) in obese children",
abstract = "Aim: Antiphospholipid (aPL) antibodies, Lipoprotein(a) [Lp(a)] and obesity are considered three independent risk factors for development of cardiovascular diseases. We investigate the presence of aPL antibodies and the Lp(a) concentration in 190 obese and 30 healthy children divided into prepubertal and pubertal, compared with healthy adults. Results: aPL antibodies were detected in 2.65{\%} of prepubertal and in 2.59{\%} of pubertal obese children. Considering results obtained by Lp(a) test, 4.4{\%} of prepubertal and 5.2{\%} of pubertal obese children and 17.5{\%} of healthy adults were at risk for development of cardiovascular diseases. Conclusion: The presence of various prothrombotic risk factors increases the probability of developing thrombosis. Considering aPL antibodies there is no statistically significant difference among the different considered groups; therefore each category has the same risk factor. The Lp(a) distribution in adults is significantly different from the Lp(a) distribution in prepubertal (p = 0.012) and pubertal (p = 0.029) obese children. There is no significant difference among prepubertal subjects (p = 0.632) as well as pubertal subjects (p = 0.465), independently from the BMI. These results suggest the control of BMI in young population to avoid the presence of the obesity as another independent prothrombotic risk factor to be added to aPL and Lp(a) in the future adulthood.",
keywords = "Antiphospholipid antibodies, Children, Lipoprotein(a), Obesity",
author = "Devis Pascut and Tanja Princi and Michela Donato and Giorgio Tamaro and Sergio Parco",
year = "2009",
month = "4",
doi = "10.1111/j.1651-2227.2008.01182.x",
language = "English",
volume = "98",
pages = "703--707",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Antiphospholipid antibodies and lipoprotein(a) in obese children

AU - Pascut, Devis

AU - Princi, Tanja

AU - Donato, Michela

AU - Tamaro, Giorgio

AU - Parco, Sergio

PY - 2009/4

Y1 - 2009/4

N2 - Aim: Antiphospholipid (aPL) antibodies, Lipoprotein(a) [Lp(a)] and obesity are considered three independent risk factors for development of cardiovascular diseases. We investigate the presence of aPL antibodies and the Lp(a) concentration in 190 obese and 30 healthy children divided into prepubertal and pubertal, compared with healthy adults. Results: aPL antibodies were detected in 2.65% of prepubertal and in 2.59% of pubertal obese children. Considering results obtained by Lp(a) test, 4.4% of prepubertal and 5.2% of pubertal obese children and 17.5% of healthy adults were at risk for development of cardiovascular diseases. Conclusion: The presence of various prothrombotic risk factors increases the probability of developing thrombosis. Considering aPL antibodies there is no statistically significant difference among the different considered groups; therefore each category has the same risk factor. The Lp(a) distribution in adults is significantly different from the Lp(a) distribution in prepubertal (p = 0.012) and pubertal (p = 0.029) obese children. There is no significant difference among prepubertal subjects (p = 0.632) as well as pubertal subjects (p = 0.465), independently from the BMI. These results suggest the control of BMI in young population to avoid the presence of the obesity as another independent prothrombotic risk factor to be added to aPL and Lp(a) in the future adulthood.

AB - Aim: Antiphospholipid (aPL) antibodies, Lipoprotein(a) [Lp(a)] and obesity are considered three independent risk factors for development of cardiovascular diseases. We investigate the presence of aPL antibodies and the Lp(a) concentration in 190 obese and 30 healthy children divided into prepubertal and pubertal, compared with healthy adults. Results: aPL antibodies were detected in 2.65% of prepubertal and in 2.59% of pubertal obese children. Considering results obtained by Lp(a) test, 4.4% of prepubertal and 5.2% of pubertal obese children and 17.5% of healthy adults were at risk for development of cardiovascular diseases. Conclusion: The presence of various prothrombotic risk factors increases the probability of developing thrombosis. Considering aPL antibodies there is no statistically significant difference among the different considered groups; therefore each category has the same risk factor. The Lp(a) distribution in adults is significantly different from the Lp(a) distribution in prepubertal (p = 0.012) and pubertal (p = 0.029) obese children. There is no significant difference among prepubertal subjects (p = 0.632) as well as pubertal subjects (p = 0.465), independently from the BMI. These results suggest the control of BMI in young population to avoid the presence of the obesity as another independent prothrombotic risk factor to be added to aPL and Lp(a) in the future adulthood.

KW - Antiphospholipid antibodies

KW - Children

KW - Lipoprotein(a)

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=61849176617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849176617&partnerID=8YFLogxK

U2 - 10.1111/j.1651-2227.2008.01182.x

DO - 10.1111/j.1651-2227.2008.01182.x

M3 - Article

VL - 98

SP - 703

EP - 707

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - 4

ER -